Page 24 - 2021_12-Haematologica-web

P. Gresele et al.
References
1. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocy- topenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384(20):1964-1965.
2. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101.
3. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124-2130.
4. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021,384(23):2202-2211.
5. Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet. 2021;397(10285):e11.
6. Muster V, Gary T, Raggam RB, WÖlfler A, Brodmann M. Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination. Lancet. 2021;397(10287):1842.
7. Shay DK, Gee J, Su JR, et al. Safety moni- toring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March- April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):680-684.
8. Rodeghiero F, Balduini CL. A new enemy is emerging in the fight against the SARS- CoV-2 pandemic. Haematologica. 2021;106 (8):2040-2041.
9. Hwang J, Lee SB, Lee SW. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines. J Autoimmun. 2021;122:102681.
10. Sangli S, Virani A, Cheronis N. Thrombosis with thrombocytopenia after the messen- ger RNA-1273 vaccine. Ann Intern Med. 2021;L21-0244.
11. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle P, Eichinger S. A pro- thrombotic thrombocytopenic disorder resembling heparin-induced thrombocy- topenia following coronavirus vaccination. Blood Transfus. 2021; 19(4): 281-283
12. SeeI,SuJR,LaleA,WooEJ,etal.UScase reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448- 2456.
13.Gresele P, Marietta M, Ageno W, et al. Management of cerebral and splanchnic vein thrombosis associated with thrombo- cytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). Blood Transfus. 2021;19(4):281- 283.
14. Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL. A monoclonal antibody specif- ic for the cellular receptor for the group B coxsackieviruses. J Virol. 1988;62(5):1647- 1652.
15. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275(5304):1320-1323.
16. Bewley MC, Springer K, Zhang YB, Freimuth P, Flanagan JM. Structural analy- sis of the mechanism of adenovirus binding to its human cellular receptor CAR.
Science. 1999;286(5444):1579-1583. 17.Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wicham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing Adenoviridae.
Science. 1999;286(5444):1568-1571.
18. Greber U, Willets M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell. 1993;75(3):477-
486.
19. Wickham TJ, Mathias P, Cheresh DA,
Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internal- ization but not virus attachment. Cell. 1993;73(2):309-319.
34. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664-670.
35. Kurosawa S, Stearns-Kurosawa DJ, Hidar N, Esmon CT. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest. 1997;100(2):411-418.
36. Gandrille S. Endothelial cell protein C receptor and the risk of venous thrombosis. Haematologica. 2008;93(6):812-816.
37. Javanmard SH, Shahsavarzadeh T, Saadatnia M. Soluble thrombomodulin and endothelial cell protein C receptor levels in patients with cerebral venous and sinus thrombosis. Eur Neurol. 2013;70(3-4):156-
20. Davison E, Diaz RM, Hart IR, Santis G,
Marshall JF. Integrin a5b1-mediated aden-
ovirus infection is enhanced by the inte- grin-activating antibody TS2/16. J Virol. 1997;71(8):6204-6207. 158.
21. Zhang Y, Bergelson JM. AD receptors. J Virol. 2005;79(19):12125-12131.
22. Honda T, Saitoh H, Masuko M, et al. The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the develop- ing mouse brain. Brain Res Mol Brain Res. 2000;77(1):19-28.
23. Patzke C, Max KEA, Behlke J, et al. The coxsackievirus-adenovirus receptor reveals complex homophilic and heterophilic inter- actions on neural cells. J Neurosci. 2010;30(8):2897-2910.
24.Nalbantoglu J, Pari G, Karpati G, et al. Expression of the primary coxsackie and adenovirus receptor is downregulated dur- ing skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther. 1999;10(6):1009-1019.
38. Gould WR, Baxi SM, Schroeder R, et al. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J Thromb Haemost. 2005;3(4):733-741.
39. Nidetz NF, Gallagher TM, Wiethoff CM. Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 bind- ing. Virology. 2018;515:150-157.
40. Allen RJ, Byrnes AP. Interaction of aden- ovirus with antibodies, complement, and coagulation factors. FEBS Letters. 2019;593 (24):3449-3460.
41. Lenman A, Muller S, Nygren MI, Frangsmyr L, Stehle T, Arnberg N. Coagulation factor IX mediates serotype- specific binding of species A adenoviruses to host cells. J Virol. 2011;85(24):13420- 13431.
42. Parker AL, McVey JH, Doctor JH, et al. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudo- typed with fibers from subgroup D. J Virol. 2007;81(7):3627-3631.
43. Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006;108(8):2554-2561.
44. Shayakhmetov DM, Gaggar A, Ni S, Li, Lieber A. Adenovirus binding to blood fac- tors results in liver cell infection and hepa- totoxicity. J Virol. 2005;79(12):7478-7491.
45. Kalyuzhniy O, Di Paolo NC, Silvestry M, et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A. 2008;105(14): 5483-5488.
46. Duffy MR, Doszpoly A, Turner G, Nicklin SA, Baker AH. The relevance of coagula- tion factor X protection of adenoviruses in human sera. Gene Ther. 2016;23(7):592-
25.
Noutsias M, Fechner H, de Jonge H, et al. Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated car- diomyopathy: implications for cardiotropic viral infections. Circulation. 2001;104(3): 275-280.
26.Rebel V, Hartnett S, Denham J, et al. Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells. Stem Cells. 2000;18 (13):176-182.
27. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus- induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediat- ing accelerated platelet clearance. Blood. 2007;109(7):2832-2839.
28. Shimony N, Elkin G, Kolodkin-Gal D, Krasny L, Urieli-Shoval S, Haviv YS. Analysis of adenoviral attachment to human platelets. Virol J. 2009;6:25.
29. Stone D, Liu Y, Shayakhmetov D, Li ZY, Ni 596.
S, Lieber A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol. 2007;81(9):4866-4871.
30. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood. 2015;125(19):2898-2907.
31. Esmon CT. Protein C. Prog Hemost Thromb. 1984;7:25-54.
32. Hamad OA, Nilsson PH, Lasaosa M, et al. Contribution of chondroitin sulfate A to the binding of complement proteins to acti- vated platelets. PLoS One. 2010;5(9): e12889.
33. Dahlbäck B, Wiedmer T, Sims PJ. Binding of anticoagulant vitamin K-dependent pro- tein S to platelet-derived microparticles. Biochemistry. 1992;31(51):12769-12777.
47. Greinacher A, Selleng K, Wesche J, et al. Towards understanding ChAdOx1 nCov- 19 vaccine-induced immune thrombotic thrombocytopenia (VITT). Research Square. 2021 Apr 20. [Epub ahead of print]
48. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther. 2004;15(1):35-46.
49. Kadkhoda K. Post-adenoviral-based COVID-19 vaccines thrombosis: a pro- posed mechanism. J Thromb Haemost. 2021;19(7):1831-1832.
50. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat
3044
haematologica | 2021; 106(12)